Autologous stem cell transplantation for pediatric solid tumors in a resource-limited setting: a single-center experience of 15 years - Takeaways - MDSpire

Autologous stem cell transplantation for pediatric solid tumors in a resource-limited setting: a single-center experience of 15 years

  • By

  • Debabrata Mohapatra

  • Deepam Pushpam

  • Sameer Bakhshi

  • Ranjit Kumar Sahoo

  • Surender K. Sharawat

  • Sandeep Agarwala

  • June 16, 2026

  • 0 min

Share

  • 1

    The study evaluated long-term outcomes of autologous stem cell transplantation (ASCT) for pediatric solid tumors in a resource-constrained environment.

  • 2

    A total of 92 patients aged 0-25 years underwent ASCT, with high-risk neuroblastoma being the most common diagnosis at 52.2%.

  • 3

    The overall 3-year overall survival (OS) rate for the cohort was 50.6%, with event-free survival (EFS) at 35.9%.

  • 4

    Three-year OS rates varied by diagnosis, with high-risk neuroblastoma at 48.5% and relapsed/refractory germ-cell tumors at 56.3%.

  • 5

    The study highlights the need for more data on ASCT outcomes in low- and middle-income countries, particularly for various pediatric solid tumors.

Original Source(s)

Autologous stem cell transplantation for pediatric solid tumors in a resource-limited setting: a single-center experience of 15 years

  • by Debabrata Mohapatra, Deepam Pushpam, Sameer Bakhshi, Ranjit Kumar Sahoo, Surender K. Sharawat, Sandeep Agarwala

  • June 16, 2026

Related Content

Pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic biomarkers for neuroblastoma risk stratification

Parabilis Sets Biotech IPO Record

The clinical-stage cancer biotech raised $670 million in an upsized Nasdaq debut, with a further $75 million expected from a concurrent Regeneron private placement

  • June 15, 2026

  • 2 min
Editorial: Cancer Immunosurveillance